Specialist Shortfalls up 74% in 5 Years, yet 4 in 5 Medical Aid Members Have No Gap Cover

As 2027 medical scheme premiums rise, members moving to cheaper plans face even bigger out-of-pocket costs

Photo by Cottonbro on Pexels

Tuesday, 17 November 2026, Johannesburg: With significant increases coming in 2027, many medical scheme members will need to decide whether to buy down to a cheaper option. However, many aren’t considering how much specialist fees have risen while medical scheme payouts have lagged.

Kaelo’s claims analysis shows that between 2021 and 2026, specialist fees rose 50% while the amounts medical schemes pay rose just 24%, lifting the typical shortfall on a specialist account by 74% over the 5-year period. Specialists set their own fees and schemes set their own rates, so the patient must settle the difference. Only about one in five scheme members has gap cover, which would cover this shortfall.

“Even members who stay on the same plan face larger shortfalls every year, and buying down increases the exposure,” says Sian MacGregor, sales director at Kaelo. “Our actuaries have shown that gap cover is not an optional extra these days, given the dynamics at play in the medical scheme landscape. It has become a necessary add-on to medical aid.”

Kaelo’s modelling shows that once a typical earner has covered their monthly expenses, they’re left with about R850, and that’s all they would have to put towards an unexpected medical bill. At that rate, the average shortfall on childbirth (R18 500) takes 22 months to repay, uterine scarring (R19 000) takes 23 months, and spinal stenosis (R30 000) takes three years. These are just three examples of common medical procedures; others can cost a lot more.

For example, a young woman with endometriosis, on a medical scheme, will face about R35 000 in shortfalls and co-payments for surgery. On a first-job salary of R20 000 a month, and without gap cover, the operation would likely be put off, but delayed intervention has consequences. Postponing treatment for uterine scarring can raise miscarriage risk in a later pregnancy by up to 33%, while a delayed colonoscopy has major implications for survival rates if cancer is found.

Kaelo has paid the annual maximum gap cover of about R210 000 on numerous claims in the past year, including cardiac and vascular surgery.

How an employer offers gap cover affects what staff pay. In one Kaelo employer group, gap cover moved from voluntary to compulsory for staff on a medical scheme. Covered employees rose from an average of 960 to nearly 3,600. Total monthly claims tripled, and that year 166 more employees who previously could not afford care could now access and claim from gap cover. At the same time, the average cost per covered employee fell by 16%.

“When cover is voluntary, the people who sign up are mostly those who already expect to claim, so costs and premiums climb,” says MacGregor. “When it is the default, the cost is spread across a bigger, healthier pool.” Kaelo projects that within five years, premiums for a group where cover is the default will be 30% to 50% lower than for the same cover offered voluntarily. Policyholders also get Dis-Chem Better Rewards, a benefit that helps offset the premium.

In addition to covering medical aid shortfalls, Kaelo Gap pays hospital co-payments upfront, so members don’t have to find the cash before a planned procedure. After a claim, trained counsellors call members to check on their overall wellbeing, such as phoning new mothers or offering support on a cancer diagnosis.

Kaelo Gap has grown about 11% year to date, across corporate and individual clients.

Members who plan to buy down on their medical scheme plan should check that their gap option is still appropriate, MacGregor advises. One Kaelo Gap option pays up to an additional 500% of the scheme rate, which may suit a comprehensive plan, while a basic plan may call for another option, which pays up to an additional 600%. Individual policies usually have a three-month waiting period, so arrange cover well before you need treatment. Individual cover starts from R219 a month.

Review Finds Insufficient Evidence to Back Medical Cannabis for Insomnia

Photo by Andrea Piacquadio

A new Cochrane review finds that existing evidence is too uncertain to determine whether medical cannabis improves sleep or daytime functioning in people with insomnia.

Insomnia is a common sleep disorder that makes it hard to fall asleep, stay asleep, or wake up not feeling refreshed. It can have a severe impact on a person’s quality of life and make a person much more vulnerable to developing anxiety or depression over time. 

Existing treatment options include cognitive behavioural therapy and drugs, including antidepressants and antipsychotics, but these vary in success. 

In recent years, there has been growing interest in medical cannabis as an alternative treatment for insomnia for its reported benefits in improving sleep. In clinical settings, this typically involves controlled, tested ratios of THC and CBD in the form of tablets, sprays or oils. However, the use of medical cannabis for insomnia remains contentious, and evidence is limited. 

No clear evidence that medical cannabis helps

Led by researchers from The Cochrane Associate Centre at the Universidad Hospital Italiano de Buenos Aires and University of Manitoba, the review included 9 studies involving 537 adults aged 18 to 76 who were treated for insomnia. Most studies focused on people with primary insomnia rather than insomnia linked to other health conditions. Eight of the nine trials compared regulated medical cannabis to a placebo; one compared it to the antidepressant amitriptyline.

Medical cannabis showed little to no clinically meaningful improvement in sleep quality and satisfaction, total sleep time, or daytime functioning compared with placebo. 

Participants taking medical cannabis were substantially more likely to experience mild adverse events, such as a dry mouth and dizziness, than those on placebo; but this was based on a small pool of studies.

Medical cannabis somewhat improved quality of life, but certainty is very low, and pooled results were compatible with anything from a slight worsening to a large improvement.
 

The main message is that the research currently available is not sufficient to reliably answer whether medical cannabis helps people with insomnia.

– Dr Lucia Varela, University of Manitoba


Dr Lucia Varela, lead author of the study from the University of Manitoba, Canada, says: “This does not mean that medical cannabis is ineffective. It means that, based on the evidence we have, we cannot draw reliable conclusions about its effectiveness for insomnia in the general population.”

Poor trials downgrade the evidence

The overall quality and certainty of the evidence were rated very low to low, largely due to risk of bias in the underlying studies, inconsistent results between trials, and small sample sizes. 

Studies varied a lot in the type of cannabis product used, which limited comparability, and the longest study only followed participants for 12 weeks. This means we can’t say much about the long-term effects.

The available data was also not very representative of broader patient groups. The data were heavily skewed towards younger people and women (72.66% of participants). Therefore, the findings may not be as applicable to men, older adults, and those with comorbidities.

The authors conclude that the evidence remains weak and uncertain, highlighting the need for higher-quality research before medical cannabis can be recommended for insomnia.

“The evidence is too weak and uncertain to draw firm conclusions about the use of medical cannabis for insomnia,” says Dr Luis Garegnani, senior author from Universidad Hospital Italiano de Buenos Aires, Argentina. “Rather than viewing the findings as either an endorsement or a rejection of medical cannabis, clinicians and patients should recognise the uncertainty and consider individual circumstances while better evidence is generated.”

By Mia Parkinson

Read the review

Source: Cochrane

‘Fossil Record’ in Stored Blood Samples Lets Scientists Trace Leukaemia back Decades Before Diagnosis

SAG Leukaemia. Credit: Scientific Animations CC0

Scientists have reconstructed how acute myeloid leukaemia (AML) develops over the decades before diagnosis, showing that in two-thirds of cases the first cancer-driving mutation had been acquired before the age of 20 – more than 50 years before diagnosis. 

Serial blood samples are a fossil record of the blood’s evolution. They let us go back in time and reconstruct when each mutation arose and how fast it grew

Jamie Blundell

The discovery could help predict whether an individual will develop the disease years – or even decades – before symptoms arise, raising the possibility of preventing the disease before it develops.

In research published today in Nature, a team at the University of Cambridge and University College London (UCL) used blood samples collected annually, some dating back 15 years before diagnosis, as a ‘fossil record’ of the disease’s development, tracing it step by step. Using ultra-sensitive DNA sequencing and mathematical modelling, they estimated when each mutation arose and how quickly the affected cells multiplied and competed with other blood cells in the years prior to AML diagnosis.

AML is an aggressive blood cancer affecting around 2,700 people in the UK each year. Only around one in six survive five years after diagnosis. Many healthy older people carry blood cells with mutations also found in leukaemia, a condition known as clonal haematopoiesis, but only a small proportion develop AML. What has not been clear is why, because the process has never been tracked year by year in the run-up to diagnosis.

The researchers used samples from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), in which around 50,000 women gave a blood sample every year for up to 11 years. The team studied 47 women who later developed AML, at an average age of 72, alongside matched samples from 46 women who stayed blood cancer-free.

This first mutation, acquired before age 20 in two-thirds of the women who developed AML, was followed by decades of slow growth – cells carrying it took years to double in number. Each additional mutation increased their growth rate around two- to three-fold, with cells carrying four cancer-driving mutations doubling in a matter of weeks.

The growth of these groups of cells, known as clones, proved remarkably predictable. Once a clone carrying a cancer-driving mutation was established, it expanded at a steady rate, slowing only when it ran out of room or was overtaken by a faster-growing clone. In practice, this means a clone’s growth rate, measured from a few blood samples today, can be used to estimate how large that clone may become years and even decades into the future.

In at least a third of the AML cases, a clone had come to dominate the blood years before diagnosis, a phenomenon known as a ‘somatic sweep’. No such sweeps were seen in the women who remained blood cancer-free. The team confirmed the link with AML risk using UK Biobank data, finding that people with these sweeps were at greatly increased risk of developing the disease. The findings highlight the importance of recognising this potential warning sign, which standard genetic analysis often overlooks by mistaking these mutations for inherited variants.

Professor Jamie Blundell from the Early Cancer Institute at the University of Cambridge, who led the study, said: “Serial blood samples are a fossil record of the blood’s evolution. They let us go back in time and reconstruct when each mutation arose and how fast it grew. What surprised us most is how predictable the growth of these clones is. Once a clone is established, its growth rate today tells you where it will be years, even decades, from now.”

He added: “Because the growth is exponential, even modestly slowing a high-risk clone over the decade or more before diagnosis could substantially reduce the chance it becomes leukaemia. This opens up strategies we can exploit to prevent these clones ever becoming leukaemia.”

Dr Caroline Watson, also from the Early Cancer Institute, and first author of the study, said: “As a haematologist, I’ve seen how suddenly AML can change someone’s life. This study shows that the changes leading to AML can build over decades, with the affected cells growing in surprisingly predictable ways.”

Dr Watson is also an Honorary Consultant Haematologist and sees patients at the Cambridge Clonal Haematopoiesis Clinic at Addenbrooke’s Hospital, the first clinic focusing on leukaemia prevention in Europe. She added: “At our clinic, we already assess and monitor people who carry blood-cell mutations that increase their risk of leukaemia. Today’s findings give us real hope of improving how we identify which of them are at greatest risk and point to a window in which prevention could one day be possible.”

Professor Usha Menon, from the UCL Institute of Clinical Trials and Methodology, who led UKCTOCS, said: “While UKCTOCS was designed to assess ovarian cancer screening, a key outcome was the establishment of a unique bioresource of serial serum samples. This resource has provided unprecedented opportunities to study how cancers develop over time and to discover and validate biomarkers for earlier detection. We owe an enormous debt of gratitude to the participants whose willingness to contribute their samples and data over many years made this possible. Their generosity is the foundation of this achievement.”

The women were diagnosed with AML between the ages of 53 and 83, and the study did not include samples taken at time of diagnosis. In around one in five cases, expanding populations of mutated cells were not detectable until one to two years before AML diagnosis, suggesting that some cases may offer a shorter warning period.

The findings point towards opportunities for early detection and prevention. The team’s modelling suggests that even a small reduction in a clone’s growth rate, compounded over the ten or more years between the second mutation and diagnosis, could substantially reduce the risk of progression to leukaemia. This raises the possibility of preventative treatments that slow these cells’ growth before leukaemia develops. Testing whether this can be achieved safely and effectively in people identified as high risk is the team’s next step.

The research was largely funded by UK Research & Innovation and Cancer Research UK.

The University of Cambridge and Addenbrooke’s Charity are fundraising for Cambridge Cancer Research Hospital, which will include the Early Cancer Institute Research Clinic, where detecting cancer at its earliest stages will be a key goal. Set to be built on the Cambridge Biomedical Campus, the hospital will bring together clinical excellence from Addenbrooke’s Hospital and world-leading researchers at the University of Cambridge. The research that takes place there promises to change the lives of cancer patients across the UK and beyond. Find out more here.

Reference

Watson, CJ, et al. Evolutionary dynamics in the years preceding acute myeloid leukaemia. Nature; 11 Nov 2026; DOI: 10.1038/s41586-026-11269-x


Creative Commons License.
The text in this work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Source: University of Cambridge

Single Iron Infusion Improved Exercise Capacity in HFpEF

Iron deficiency is a common challenge in people with heart failure with preserved ejection fraction
A randomised trial found that intravenous iron repletion led to functional benefits after 12 weeks for these patients

Right side heart failure. Credit: Scientific Animations CC4.0

A new study by investigators from the Mass General Brigham Heart and Vascular Institute found that a single iron infusion improved exercise capacity in people with heart failure with preserved ejection fraction (HFpEF) and iron deficiency. The findings suggest that replenishing iron could help address the physical limitations associated with this condition. Results were presented at the 2026 American Heart Association Scientific Sessions and published simultaneously in Circulation.

The IRON-MET HFpEF trial enrolled 65 participants with symptomatic HFpEF and iron deficiency, which affects more than 50% of patients with HFpEF. Their median age was 68 years, and 72% of participants were women. For the study, 44 participants were randomized to receive one 1000mg IV dose of ferric derisomaltose and 21 to receive placebo. Iron was administered intravenously because previous studies have demonstrated that oral iron is not beneficial in patients with other forms of heart failure, likely due to poor gastrointestinal absorption.

All participants underwent cardiopulmonary exercise testing before and 12 weeks after the infusion. At 12 weeks, peak oxygen uptake or VO2, a key indicator of cardiorespiratory fitness, improved by approximately 10% in the intervention group and was unchanged in the placebo group.

“Patients living with HFpEF are burdened with severe limitations in exercise tolerance,” said lead author Gregory D. Lewis, MD, director of Heart Failure at the Mass General Brigham Heart and Vascular Institute and professor of Medicine at Harvard Medical School. “In the first study to comprehensively evaluate exercise response patterns to iron repletion in patients with HFpEF and iron deficiency, we found that ferric derisomaltose improved multiple measures of exercise capacity.”

Measurements of the bioavailability of iron in the blood improved with intravenous iron, as did pre-specified secondary measures of exercise capacity, including 6-minute walk distance, VO2 at the anaerobic threshold, and New York Heart Association Functional Class, compared with those who received placebo. However, the authors note that patient-reported health scores, based on a comprehensive questionnaire, did not differ significantly between groups. There were no serious adverse events associated with the iron supplementation.

As the study was conducted in a small, predominantly white population and participants were assessed at 12 weeks, the authors advocate for further studies to determine whether IV iron has benefits in diverse populations and whether these benefits last over longer time periods.

“The improvement we observed in peak VO2 represents a clinically meaningful increment for patients with heart failure,” said senior author Rajeev Malhotra, MD, who is Associate Director of the Cardiopulmonary Exercise Laboratory at the Mass General Brigham Heart and Vascular Institute and associate professor of Medicine at Harvard Medical School. “The next step is to determine whether IV iron can improve long-term clinical outcomes in patients with HFpEF.”

Source: Mass General Brigham

Could These Drugs Improve Survival in ARDS?

Photo by Anna Shvets

A clinical trial starting on Nov. 19 at UC San Francisco could lead to the first precision medicines for a rapidly progressing, life-threatening breathing disorder.

The disorder, acute respiratory distress syndrome (ARDS), affects 1 in 10 patients in intensive care units (ICUs) and usually follows pneumonia, severe infection, or accident-related trauma. ARDS causes inflammation and fluid buildup in the lungs, making it difficult for oxygen to enter the bloodstream.

Currently, treatment for ARDS largely consists of supportive care, including mechanical ventilation, which delivers air enriched with oxygen into the lungs and can be lifesaving but may also worsen lung injury. For 35% to 45% of patients, ARDS is fatal.  

Can a patient walk independently? Are they able to return to work?

Michael Matthay, MD, professor of medicine and anaesthesia at UCSF

The PANTHER trial is funded by the U.S. Department of Defense and will run at 10 institutions nationwide. Additional sites will be located abroad. The study builds on years of research by Carolyn Calfee, MD, and Michael Matthay, MD, professors of medicine and anesthesia at UCSF and co-directors of the Center for Precision Research in Critical Care, a new center dedicated to improving patient outcomes in the ICU through implementation of precision medicine.

Their research has identified two biological forms of ARDS, hyperinflammatory and the less inflamed hypo-inflammatory, raising the possibility that precision medicine for each could lead to better outcomes.  

“We found that some treatments that appeared to improve survival in one form showed no benefit when patients with both forms were analysed together,” said Calfee, co-principal investigator of the UCSF site and one of the leads of the global PANTHER trial. 

Researchers plan to enroll 300 patients at the U.S. sites.  

Patients will first receive a blood test for biomarkers that classify them as having hyperinflammatory or hypo-inflammatory ARDS. One-third will be randomly assigned to receive usual care, which may include lung-protective mechanical ventilation, positioning patients on their stomachs to improve oxygen levels, and managing fluids to reduce fluid buildup in the lungs.

The remaining patients will receive usual care plus one of two drugs. The first, simvastatin, is widely used to lower cholesterol and also has broad anti-inflammatory effects; while baricitinib, which targets specific inflammatory pathways and is approved to treat rheumatoid arthritis, has shown some benefit in treating ARDS resulting from severe COVID-19.

PANTHER is an adaptive trial platform that enables the study to change as evidence accumulates. Promising new drugs can be added, while drugs that are shown to be ineffective will be dropped.  

The study will measure survival and the number of days during the first 28 days that patients live without major life support treatments, such as mechanical ventilation or drugs to maintain blood pressure.

“Additionally, we will be looking at the extent to which a patient can recover,” said Matthay, co-principal investigator of the UCSF site and a member of PANTHER’s biobanking team, which collects blood samples. “Can a patient walk independently? Are they able to return to work? Are they recovering their cognitive skills, and do they have the muscle strength to perform everyday tasks?”

Many people who survive ARDS face long-term cognitive impairment and significant physical limitations, according to the National Heart, Lung, and Blood Institute. 

By Suzanne Leigh

Source: University of California San Francisco

Trial Supports Wider Use of Adalimumab in Uveitis

Image depicting uveitis, created with AI.

A UK clinical trial has shown that adalimumab protects sight in a far wider group of patients with non-infectious uveitis than previously recognised.

Findings published in eClinicalMedicine suggest eligibility criteria should be widened.

Uveitis is the inflammation of the uvea, which is the middle, pigmented layer of the eye containing the iris, ciliary body, and choroid. Non-infectious uveitis is a leading cause of blindness in high-income countries. Adalimumab is already used in the NHS for arthritis and some forms of ocular inflammation and is the only non-steroid treatment licensed in the UK for uveitis.

The ASTUTE trial, co-led by Oxford University Hospitals and Bristol NHS Foundation Trust, recruited patients at 18 UK hospitals. All received adalimumab for 16 weeks plus standard care. Responders were then randomised to continue the drug or placebo (double-blind).

At one year, 31.4% of those continuing adalimumab experienced relapse or needed further treatment, versus 59% on placebo. NICE guidance (2017) funds the drug only for a narrow set of patients; ~85% of those randomised in ASTUTE would not have met the criteria. In this “excluded” group, continued treatment reduced treatment-failure risk by 63%, with the same overall benefit.

Dr Srilakshmi Sharma, Consultant Medical Ophthalmologist at the Oxford Eye Hospital and co-chief investigator, said: “We set out to answer a question that patients have been asking us in clinic for years, which is whether this drug would help them if only they were allowed to have it. The answer is yes, for many of them. These are people who come to our clinics with their sight at risk, and who we currently have to tell that the funding rules do not cover them. We now have UK trial evidence, from NHS clinics and patients, that the rules are drawn in the wrong place.”

Side-effects were no more common with adalimumab than placebo. University of Oxford health economists estimated an extra annual cost of £662 per patient and £2320 per treatment failure avoided; a cheaper biosimilar was used.

Co-chief investigator Dr Andrew Dick (University of Bristol and UCL) said: “This trial was designed to be difficult to argue with. We treated everyone first, so we knew who responded, and only then did we randomise. That design let us show, cleanly, that stopping the drug in people who are doing well on it leads to relapse in most of them. The implication for practice is straightforward: when it works, it needs to be continued, and in many more patients than are currently eligible.”

Patients helped design the trial. It was supported by the Birdshot Uveitis Society and the NIHR Health Technology Assessment Programme and NIHR Biomedical Research Centres at Moorfields and Oxford. Annie Folkard (Birdshot Uveitis Society) noted that more than a hundred participants contributed over years and deserve an answer that could change access. The team has submitted the eligibility findings to NICE.

Source: Oxford University Health Service

Nearly Half of Deaths Among Adults with Down Syndrome are from Avoidable Causes

Photo by Nathan Anderson on Unsplash

Roughly 47% of deaths among adults with Down syndrome in England were from causes classed as avoidable, with epilepsy and pneumonia as the leading treatable causes, and COVID-19 the leading preventable cause, according to a new study led by researchers at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London.

Nearly half of deaths among adults with Down syndrome in England are from causes that could potentially have been prevented or treated, according to a new study led by researchers at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London.

Published in JAMA Network Open, the study analysed the deaths of 3381 adults with Down syndrome and 15 347 other adults with a learning disability, recorded between 2016 and 2023 by the LeDeR programme (Learning from Lives and Deaths – people with a learning disability and autistic people (LeDeR)). The researchers compared them with Office for National Statistics data on more than four million deaths in the general population.

The researchers classed 47% of deaths among adults with Down syndrome as avoidable, meaning they happened before the age of 75 and could have been prevented through public health measures or treated with timely healthcare. Among other adults with a learning disability, the figure was 45%. Most avoidable deaths among adults with Down syndrome were from treatable causes, which accounted for 29% of all deaths in the group, with epilepsy (8.6%) and pneumonia (6.0%) the most common. Deaths related to epilepsy were more frequent than in either comparison group. COVID-19 was the leading preventable cause, accounting for 9.9% of deaths.

We have shown that individuals with Down syndrome have high rates of avoidable deaths due to treatable conditions such as lung infections. This is concerning and requires action, including vaccination programmes for common infections such as flu, COVID-19 and pneumococcal bacteria. People with Down syndrome would also benefit from monitoring for the complications of Alzheimer’s disease, which was a common cause of death.

André Strydom, Professor of Intellectual Disabilities at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London

Adults with Down syndrome died at a median age of 59.5 years, compared with 63.8 for other adults with a learning disability and 81.9 for the general population. After accounting for other factors, having Down syndrome was associated with higher odds of an avoidable death than among other adults with a learning disability, and with dying younger from an avoidable cause.

Within the Down syndrome group, people from ethnic minority backgrounds had higher odds of an avoidable death, and those living in more deprived areas died from avoidable causes at a younger age. Asthma, diabetes and osteoporosis were also linked to higher odds of avoidable death.

The way a death is recorded determines whether it can be recognised as avoidable. Death certificates frequently list Down syndrome as the underlying cause, which obscures the condition that led to the death. By taking the next condition listed instead, we were able to classify these deaths according to their actual cause, rather than as an inevitable consequence of the syndrome. Without that step, a substantial avoidable burden remains undetected.

Lili Bokor, first author of the study and Research Assistant at the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London

Dr Rory Sheehan, at the Institute of Psychiatry, Psychology & Neuroscience, said: “This study shows that people with Down syndrome may have different patterns of morbidity and mortality compared to other people with a learning disability. Data collected through LeDeR have helped us to understand these differences which should enable professionals and health services to adapt their approaches, identify issues earlier, and provide more targeted intervention and treatment.”

Avoidable Mortality in Adults With Down Syndrome or With Other Intellectual Disabilities (Bokor, Yu, Carter, Chauhan, Sheehan, Strydom) is published in JAMA Network Open. DOI: 10.1001/jamanetworkopen.2026.43229

Source: King’s College London

How a New Generation of Gauteng Vets is Reimagining the Vet Visit

Photo by Judy Beth Morris on Unsplash

New Stats SA data shows pets are part of nearly a quarter of South African households, as a University of Pretoria veterinary hospital marks the first year of its specialist cat care facility.

2026 – South Africa is home to an estimated 2 million household cats, according to Statistics South Africa’s 2025 General Household Survey. The survey found that nearly a quarter of South African households own pets.

Ahead of September, which is recognised internationally as Animal Pain Awareness Month, the figures come at a time of growing demand for high quality, innovative and accessible pet healthcare services, offering an opportunity to reflect on how South Africans care for their animals. For cat owners, that can be particularly important because illness and pain are not always easy to spot. Changes in appetite, grooming, movement, behaviour or routine can sometimes be the first signs that something is wrong.

The timing is significant for the University of Pretoria’s Onderstepoort Veterinary Academic Hospital, which is marking more than a year since opening its specialist cat care centre. The unit is Gauteng’s first and South Africa’s second Gold Status facility and has treated more than 2000 feline patients since opening.

Rethinking the vet visit

Anyone who has tried to get a cat into a carrier knows that getting to the vet can sometimes feel like an event in itself. Once there, unfamiliar sights, sounds, smells and handling can add to the stress. For some cats, that can make an examination more difficult for both the animal and the veterinary team.

The specialist facility was developed in partnership with pet food giant Royal Canin to address those challenges by designing the veterinary environment around the particular needs of cats. Gold Status is the highest level in the Cat Friendly Clinic programme. It recognizes clinics that meet defined standards covering clinical facilities, veterinary knowledge and skills, and cat-centred care.

The facility includes dedicated spaces and separate waiting and consultation rooms, with attention paid to factors such as sight, sound and smell. It also uses low stress handling and provides training for staff and students. The result is an approach that goes beyond creating a separate waiting area. The physical environment, handling techniques and clinical practices are considered together as part of the patient’s care.

A year of putting the approach into practice

Since opening, the specialist clinic has treated cats with a range of conditions. The wider hospital also has a dedicated intensive care unit for cats, an isolation ward for feline outpatients and a separate area for cats within the small animal clinic.

As a pioneering teaching hospital, it trains approximately 180 veterinary students and 38 veterinary nursing students each year, supported by 90 clinicians and 42 professional nurses. Students gain practical experience they can take into veterinary practices across South Africa.

Tricky patients

Cats can be remarkably good at hiding signs that they are unwell. A change in appetite, grooming, movement, behaviour or routine may be subtle, but it can also be an indication that something is wrong. Stress can add another layer to the challenge. A frightened or highly stressed cat may be more difficult for a veterinary team to examine, potentially making it harder to assess what is happening. A calmer environment and appropriate handling can give the veterinary team a better opportunity to examine the patient and provide appropriate care.

For owners, the aim is a veterinary visit that feels less daunting. For veterinary teams, it is about creating better conditions for assessment and treatment. For future vets, it is about learning how the environment and approach to care can affect the patient experience.

The bigger picture

The partnership between the University of Pretoria and Royal Canin brings together veterinary education, clinical practice and private sector support, demonstrating how collaboration can help strengthen veterinary expertise in South Africa.

The role of veterinary care extends well beyond the wellbeing of household pets. It is essential to the health and welfare of animals across our communities, from domestic pets and farm livestock to South Africa’s unique indigenous wildlife, while also supporting food safety, the agricultural economy and efforts to prevent diseases from passing from animals to humans.

What the experts say

“At Onderstepoort, we believe feline medicine begins with feline dignity,” said Dr Alfred Kgasi, Director of the Onderstepoort Veterinary Academic Hospital. “Our students learn that a calm cat is a diagnosable cat, and that respect for the patient transforms outcomes for the owner, the clinician and the animal.”

“Royal Canin has always believed that supporting veterinary professionals means investing in the environments where care happens,” said Frank Chadinha, General Manager for Royal Canin South Africa. “By partnering with the University of Pretoria to develop this Gold Cat Friendly facility, we are helping create better experiences for cats today while supporting the veterinarians who will care for South Africa’s pets for decades to come.”

TB Killed 53 000 People in SA Last Year, According to the WHO

In 2025, around 235 000 people in South Africa had TB, and about 53 000 lost their lives to the disease. Photo: Unsplash

By Marcus Low for Spotlight

The number of people falling ill with TB in South Africa is declining year-on-year, but the number of deaths due to the disease remains stubbornly high.

For An estimated 235 000 people in South Africa fell ill with tuberculosis (TB) in 2025, while around 53 000 died of the disease. This is according to the World Health Organization’s (WHO) latest TB estimates, published this week alongside its Global Tuberculosis Report 2026. You can see the WHO’s TB country profile for South Africa here.

There is a clear downward trend in the number of people falling ill with TB. According to the WHO, South Africa’s TB incidence rate has declined by 63% since 2015. By contrast, the absolute number of annual deaths due to TB have declined by only 19% over the same period.

South Africa’s TB epidemic continues to be closely intertwined with HIV. Of the 235 000 people who fell ill with TB in 2025, an estimated 139 000 were living with HIV, and of the 53 000 TB deaths, just over half (27 000) were in people with HIV.

There were an estimated 14 000 cases of drug-resistant TB in the country in 2025.

The numbers in context

The new WHO TB incidence estimates are substantially lower than estimates from Thembisa, the leading mathematical model of HIV and TB in South Africa. According to Thembisa, an estimated 306 000 people aged 15 and older fell ill with TB in South Africa in 2025. The mortality figures are much closer though, with Thembisa also estimating 53 000 TB deaths in 2025 (although its estimate is only for people aged 15 and older).

The WHO and Thembisa estimates of the number of people who died of TB in 2025 are both more than double the numbers reported by Statistics South Africa (just under 19 000 in 2024). This difference is not unexpected since the WHO and Thembisa produced model estimates, while Stats SA’s mortality figures are essentially just a count of what is indicated on death notifications. There is good evidence showing that certain conditions are systematically under-reported on death notifications in South Africa.

A further nuance is that the WHO’s headline figure of 235 000 people falling ill with TB refers only to people who fell ill with TB in 2025. Many people who first fell ill with TB in 2024 would still have been ill with TB in 2025, and thus the total number of people who were ill with TB in 2025 is substantially higher than 235 000.

‘Missing cases’

Much has been made in recent years, including by Spotlight, about the many people who fall ill with TB who are not diagnosed or diagnosed late, a group sometimes referred to as the ‘missing cases’.

The number of people diagnosed with TB every year in South Africa has generally hovered at around 200 000. But while that number has been relatively stable, the WHO’s estimates of the actual number of TB cases have declined from over 300 000 to the current 235 000. If these estimates are accurate, then the number of ‘missing cases’ is only around 35 000, a far distance from the estimates of over 100 000 just five or so years ago.

It would be premature however to conclude that non-diagnosis or late diagnosis is no longer a problem in our TB response. First, the WHO itself is clear that its 235 000 estimate is very uncertain – their 95% uncertainty interval places the real number in the range from 148 000 to 342 000. It is also worth keeping in mind Thembisa’s much higher estimate of 306 000 people 15 and older falling ill with TB in 2025. And second, there is much good evidence showing that people with TB symptoms in South Africa are often not diagnosed, or diagnosed late.

According to a recent modelling study, a major gap in South Africa’s TB response is that many people who present at South Africa’s public sector clinics with TB symptoms are not offered TB tests. The classic symptoms of TB include persistent cough, night sweats, fatigue, chest pain, fever, and unexplained weight loss. The modelling suggests that simply testing more of the people presenting with these symptoms is one of the most effective things we can do in the fight against TB.

The bigger picture

Globally, an estimated 10.6 million people fell ill with TB in 2025 and 1.1 million people died from TB. Of the 10.6 million, only 8.4 million were diagnosed, leaving an estimated 2.2 million either undiagnosed or unreported, according to the WHO.

“The continued decline in TB cases and deaths is very encouraging, especially given the challenges many countries have faced from funding cuts,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General, in a media statement. “Many governments have dug deeper into their own budgets to protect the gains they have made. And yet, more than one million people still die each year from a disease that is preventable and treatable. We urge countries and partners to urgently expand access to TB services, protect essential funding and accelerate the development of new tools to end this epidemic.”

“With deaths falling by 35% since 2015 and treatment saving an estimated 86 million lives since 2000, the world has reached the first mortality milestone of WHO’s End TB Strategy, although five years later than planned. And progress has come too slowly,” the WHO said in its media release. “Since 2015, the global TB incidence rate (new cases per 100 000 population) has declined by 14%, far short of the 50% reduction milestone for 2025, and TB remains the leading cause of death from a single infectious agent.”

*This article was first published by Spotlight – health journalism in the public interest. Sign up to the Spotlight newsletter.

Antibiotics, Vaccinations and Anti-inflammatory Medication Linked to Reduced Risk of Dementia

Photo by cottonbro studio

Antibiotics, antivirals, vaccinations and anti-inflammatory medication are associated with reduced risk of dementia, according to new research that looked at health data from over 130 million individuals.

We urgently need new treatments to slow the progress of dementia, if not to prevent it. If we can find drugs that are already licensed for other conditions, then we can get them into trials much faster than we could do for an entirely new drug

Ben Underwood

The study, led by researchers from the universities of Cambridge and Exeter, identified several drugs already licensed and in use that have the potential to be repurposed to treat dementia.

Dementia is a leading cause of death in the UK and can lead to profound distress in the individual and among those caring for them. It has been estimated to have a worldwide economic cost in excess of US$1 trillion dollars.

Despite intensive efforts, progress in identifying drugs that can slow or even prevent dementia has been disappointing. Until recently, dementia drugs were effective only for symptoms and have a modest effect. Recently, lecanemab and donanemab have been shown to reduce the build-up in the brain of amyloid plaques – a key characteristic of Alzheimer’s disease – and to slow down progression of the disease, but the National Institute for Health and Care Excellence (NICE) concluded that the benefits were insufficient to justify approval for use within the NHS.

Scientists are increasingly turning to existing drugs to see if they may be repurposed to treat dementia. As the safety profile of these drugs is already known, the move to clinical trials can be accelerated significantly.  

Dr Ben Underwood, from the Department of Psychiatry at the University of Cambridge and Cambridgeshire and Peterborough NHS Foundation Trust, said: “We urgently need new treatments to slow the progress of dementia, if not to prevent it. If we can find drugs that are already licensed for other conditions, then we can get them into trials and – crucially – may be able to make them available to patients much, much faster than we could do for an entirely new drug. The fact they are already available is likely to reduce cost and therefore make them more likely to be approved for use in the NHS.”

In a study published today in Alzheimer’s and Dementia: Translational Research & Clinical Interventions, Dr Underwood, together with Dr Ilianna Lourida from the University of Exeter, led a systematic review of existing scientific literature to look for evidence of prescription drugs that altered the risk of dementia. Systematic reviews allow researchers to pool several studies where evidence may be weak, or even contradictory, to arrive at more robust conclusions.

In total, the team examined 14 studies that used large clinical datasets and medical records, capturing data from more than 130 million individuals and 1 million dementia cases. Although they found a lack of consistency between studies in identifying individual drugs that affect the risk of dementia, they identified several drug classes associated with altered risk.

One unexpected finding was an association between antibiotics, antivirals and vaccines, and a reduced risk of dementia. This finding supports the hypothesis that common dementias may be triggered by viral or bacterial infections, and supports recent interest in vaccines, such as the BCG vaccine for tuberculosis, and decreased risk of dementia.

Anti-inflammatory drugs such as ibuprofen were also found to be associated with reduced risk. Inflammation is increasingly being seen to be a significant contributor to a wide range of diseases, and its role in dementia is supported by the fact that some genes that increase the risk of dementia are part of inflammatory pathways.

The team found conflicting evidence for several classes of drugs, with some blood pressure medications and anti-depressants and, to a lesser extent, diabetes medication associated with a decreased risk of dementia and others associated with increased risk.

Dr Ilianna Lourida from the National Institute for Health and Care Research Applied Research Collaboration South West Peninsula (PenARC), University of Exeter, said: “Because a particular drug is associated with an altered risk of dementia, it doesn’t necessarily mean that it causes or indeed helps in dementia. We know that diabetes increases your risk of dementia, for example, so anyone on medication to manage their glucose levels would naturally also be at a higher risk of dementia – but that doesn’t mean the drug increases your risk.

“It’s important to remember that all drugs have benefits and risks. You should never change your medicine without discussing this first with your doctor, and you should speak to them if you have any concerns.”

The conflicting evidence may also reflect differences in how particular studies were conducted and how data was collected, as well as the fact that different medications even within the same class often target different biological mechanisms.

The UK government is supporting the development of an Alzheimer’s trial platform to evaluate drugs rapidly and efficiently, including repurposed drugs currently used for other conditions.

“Pooling these massive health data sets provides one source of evidence which we can use to help us focus on which drugs we should try first,” said Dr Underwood. “We’re hopeful this will mean we can find some much-needed new treatments for dementia and speed up the process of getting them to patients.”

Reference
Underwood, BU & Lourida, I et al. Data-driven discovery of associations between prescribed drugs and dementia risk: A systematic review. Alz & Dem; 21 Jan 2025; DOI: 10.1002/trc2.70037


Creative Commons License.
Republished from the d under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. 

Source: The University of Cambridge